IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

分组1 - IGM Biosciences, Inc. reported quarterly earnings of $1.58 per share, exceeding the Zacks Consensus Estimate of a loss of $0.3 per share, and showing a significant improvement from a loss of $0.79 per share a year ago, resulting in an earnings surprise of +626.67% [1] - The company posted revenues of $143.62 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4,388.22%, compared to revenues of $1.25 million in the same quarter last year [2] - IGM Biosciences has surpassed consensus EPS estimates two times over the last four quarters, while also topping consensus revenue estimates twice during the same period [2] 分组2 - The stock has underperformed significantly, losing about 79.4% since the beginning of the year, while the S&P 500 has gained 8.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.31 on revenues of $3.21 million, and for the current fiscal year, it is -$1.65 on revenues of $1.75 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8]